S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
LRMR · Larimar Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Larimar Therapeutics Inc (LRMR)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.40
-0.05
(-1.84%)
● At close: October 21 at 4:00:00 PM EDT
$2.42
+0.00
(+0.00%)
Overnight:
11:15:12 PM EDT
DAY'S RANGE
$2.40
$2.40
$2.54
52-WEEK RANGE
$2.40
$1.92
$6.42
What's happening
- LRMR is down 1.84% today, trading at $2.40. — Live quote
- Volume today (124,766) is well below its 3-month average of 1,729,020. (Finnhub fundamentals)
- Reports earnings on 2026-11-05 (after market close), 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.30 actual vs. $-0.39 estimated (+22.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
LRMR
-35.96%
vs S&P 500
-48.74%
1-YEAR RETURN
LRMR
-43.91%
vs S&P 500
-58.47%
6-MONTH RETURN
LRMR
-48.31%
3-MONTH RETURN
LRMR
-37.91%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.30
Est. $-0.39
BEAT +22.8%
2026-04-26 (Q1 2026)
$-0.31
Est. $-0.55
BEAT +43.2%
2026-01-26 (Q4 2025)
$-0.73
Est. $-0.52
MISS -41.2%
2025-10-26 (Q3 2025)
$-0.61
Est. $-0.41
MISS -48.0%
Valuation Measures & Ratios
Enterprise Value4$156.1M
Forward P/E5—
PEG Ratio6-0.05
Price / Sales (TTM1)—
Price / Book72.49
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-137.39%
Return on Assets (ROA9)-97.65%
Avg Volume (3M)1,729,020
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | — | — | $252.2M | $6.1M | $4.5M |
| P/E | — | — | -2.13 | -0.07 | -0.06 |
| Price/Book | — | — | 1.81 | 0.05 | 0.03 |
| ROE | — | — | -85.35% | -77.25% | -56.19% |
| ROA | — | — | -63.34% | -61.73% | -47.63% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short15,369,771
Change from Prior Settlement+10.62%
% of Float—
Days to Cover (Short Ratio)8.70
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-01; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -43.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LRMR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$34.4M | -$31.1M | -$49.5M | -$27.8M | -$31.2M | -$18.3M | -$24.6M | -$16.7M |
| Net income | -$32.8M | -$29.6M | -$47.7M | -$26.2M | -$29.3M | -$15.5M | -$21.6M | -$14.7M |
| EPS (diluted) | — | — | $-0.61 | $-0.41 | $-0.46 | $-0.24 | $-0.34 | $-0.27 |
| EPS (basic) | — | — | $-0.61 | $-0.41 | $-0.46 | $-0.24 | $-0.34 | $-0.27 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $165.3M | $208.5M | $145.8M | $187.3M | $150.0M | $170.2M | $200.2M | $219.0M |
| Total liabilities | $37.9M | $50.5M | $67.8M | $48.3M | $30.1M | $25.9M | $28.4M | $20.6M |
| Stockholders' equity | $127.4M | $158.0M | $78.1M | $139.0M | $119.9M | $144.3M | $171.8M | $198.4M |
| Total current assets | $160.7M | $205.0M | $142.0M | $183.2M | $145.6M | $165.5M | $195.3M | $213.3M |
| Total current liabilities | $34.2M | $47.8M | $64.8M | $45.1M | $26.6M | $22.1M | $24.4M | $16.3M |
| Cash & equivalents | $92.7M | $177.9M | $85.4M | $90.1M | $20.6M | $21.1M | $33.2M | $35.1M |
| Property, plant & equipment | $639.0K | $558.0K | $622.0K | $709.0K | $797.0K | $855.0K | $881.0K | $779.0K |
| Other non-current assets | $480.0K | $504.0K | $523.0K | $542.0K | $561.0K | $582.0K | $596.0K | $621.0K |
| Accounts payable | $7.6M | $8.6M | $5.2M | $11.1M | $4.2M | $2.3M | $2.4M | $1.7M |
| Accrued liabilities | $25.4M | $38.1M | $58.5M | $32.9M | $21.4M | $18.8M | $20.9M | $13.6M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $103.0K | $103.0K | $83.0K | $86.0K | $64.0K | $64.0K | $64.0K | $64.0K |
| Retained earnings | -$497.2M | -$464.4M | -$434.8M | -$372.3M | -$324.6M | -$298.4M | -$269.2M | -$240.3M |
| Accumulated other comprehensive income (loss) | -$12.0K | $6.0K | $54.0K | $66.0K | -$9.0K | $54.0K | $148.0K | $358.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$44.0M | -$44.6M | -$67.3M | — | -$19.4M | -$26.5M | -$21.8M | -$24.5M |
| Investing cash flow | -$40.9M | $29.0M | $67.0M | — | $18.8M | $14.4M | $19.2M | $27.3M |
| Financing cash flow | -$435.0K | $108.1M | $65.1M | — | $0 | — | $36.0K | $30.0K |
| Free cash flow | -$44.2M | — | -$67.3M | — | -$19.4M | -$26.6M | -$22.0M | -$24.6M |
| Capital expenditures | $130.0K | — | $0 | $23.0K | $19.0K | $49.0K | $179.0K | $62.0K |
| Share-based compensation | $2.1M | $2.0M | $1.6M | $1.8M | $1.8M | $1.8M | $2.4M | $2.0M |
| Change in accounts payable | -$557.0K | $2.9M | -$5.8M | $6.9M | $1.9M | -$150.0K | $738.0K | -$1.2M |
| Purchases of investments | $63.3M | — | $0 | $3.5M | $27.6M | $52.5M | $38.6M | $22.7M |
| Sales/maturities of investments | — | — | $34.0M | $36.5M | $113.5M | — | $58.0M | $50.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M |
| EPS (diluted) | — | $-1.32 | $-0.84 | $-1.37 | $-2.95 |
| EPS (basic) | — | $-1.32 | $-0.84 | $-1.37 | $-2.95 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M |
| Stockholders' equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M |
| Total current assets | $142.0M | $195.3M | $90.2M | $120.7M | $72.2M |
| Total current liabilities | $64.8M | $24.4M | $9.5M | $10.7M | $8.8M |
| Cash & equivalents | $85.4M | $33.2M | $26.7M | $26.8M | $70.1M |
| Property, plant & equipment | $622.0K | $881.0K | $684.0K | $831.0K | $1.0M |
| Other non-current assets | $523.0K | $596.0K | $659.0K | $638.0K | $669.0K |
| Accounts payable | $5.2M | $2.4M | $1.3M | $1.7M | $1.7M |
| Accrued liabilities | $58.5M | $20.9M | $7.4M | $8.4M | $6.6M |
| Long-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $83.0K | $64.0K | $43.0K | $43.0K | $18.0K |
| Retained earnings | -$434.8M | -$269.2M | -$188.6M | -$151.6M | -$116.2M |
| Accumulated other comprehensive income (loss) | $54.0K | $148.0K | $81.0K | -$31.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M |
| Investing cash flow | $100.3M | -$85.4M | $33.4M | -$91.0M | $24.2M |
| Financing cash flow | $65.1M | $161.9M | $30.0K | $75.3M | $19.9M |
| Free cash flow | -$113.3M | -$71.3M | -$33.6M | -$27.7M | -$42.4M |
| Capital expenditures | $91.0K | $515.0K | $164.0K | $100.0K | $333.0K |
| Share-based compensation | $7.0M | $8.8M | $7.6M | $6.6M | $5.5M |
| Change in accounts payable | $2.8M | $1.1M | -$403.0K | $26.0K | -$974.0K |
| Purchases of investments | $83.6M | $227.9M | $101.2M | $133.6M | $8.2M |
| Sales/maturities of investments | $184.0M | $143.0M | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LRMR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-22 to 2026-09-29
Recent transactions
- Insiders have net bought 50,000 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: Harlow John B. Jr. (President and COO) — Grant / award of 50,000 shares on 2026-09-29.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)50,000 sh(1 txns)
Sales (open market)0 sh(0 txns)
Net Shares+50,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Harlow John B. Jr. | President and COO | Grant / award | 2026-09-29 | 50,000 |
| Hamilton Thomas Edward | Reporting person | Open market purchase | 2026-07-06 | 50,000 |
| Flynn James E | Director | Open market purchase | 2026-02-27 | 1,084,010 |
| THOMAS FRANK E | Reporting person | Open market purchase | 2026-02-27 | 5,000 |
| SHERMAN JEFFREY W | Reporting person | Open market purchase | 2026-02-27 | 5,000 |
| Shankar Gopi | Chief Development Officer | Grant / award | 2026-01-26 | 25,637 |
| Clayton Russell | Chief Medical Officer | Grant / award | 2026-01-26 | 25,637 |
| BEN-MAIMON CAROLE | President and CEO | Grant / award | 2026-01-26 | 100,100 |
| Celano Michael | Chief Financial Officer | Grant / award | 2026-01-26 | 37,604 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Harlow John B. Jr. | President and COO | Grant / award | 50,000 | $0.00 |
| 2026-07-06 | Hamilton Thomas Edward | Reporting person | Open market purchase | 50,000 | $3.34 |
| 2026-02-27 | Flynn James E | Director | Open market purchase | 1,084,010 | $5.00 |
| 2026-02-27 | Flynn James E | Director | Open market purchase | 1,084,012 | $5.00 |
| 2026-02-27 | Flynn James E | Director | Open market purchase | 831,978 | $5.00 |
| 2026-02-27 | Flynn James E | Director | Open market purchase | 2,000,000 | $5.00 |
| 2026-02-27 | Hamilton Thomas Edward | Reporting person | Open market purchase | 100,000 | $5.00 |
| 2026-02-27 | THOMAS FRANK E | Reporting person | Open market purchase | 5,000 | $5.00 |
| 2026-02-27 | SHERMAN JEFFREY W | Reporting person | Open market purchase | 5,000 | $5.00 |
| 2026-01-26 | Shankar Gopi | Chief Development Officer | Grant / award | 25,637 | $0.00 |
| 2026-01-26 | Clayton Russell | Chief Medical Officer | Grant / award | 25,637 | $0.00 |
| 2026-01-26 | BEN-MAIMON CAROLE | President and CEO | Grant / award | 100,100 | $0.00 |
| 2026-01-26 | Celano Michael | Chief Financial Officer | Grant / award | 37,604 | $0.00 |
| 2025-07-31 | Flynn James E | Director | Open market purchase | 3,387,529 | $3.20 |
| 2025-07-31 | Flynn James E | Director | Open market purchase | 3,387,539 | $3.20 |
| 2025-07-31 | Flynn James E | Director | Open market purchase | 2,599,932 | $3.20 |
| 2025-01-22 | Shankar Gopi | Chief Development Officer | Grant / award | 23,306 | $0.00 |
| 2025-01-22 | Clayton Russell | Chief Medical Officer | Grant / award | 23,306 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:31 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-01 | 4 | 2026-09-29 | View on SEC.gov → |
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-06-29 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-05-20 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-20 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-20 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-20 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-20 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-20 | 4 | 2026-05-19 | View on SEC.gov → |
Recent news
Headlines about LRMR (Larimar Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Form 4 Larimar Therapeutics Inc: John B. Harlow Jr (President and COO) For: 29 September
Investing.com UK · 2026-10-19 -
Larimar Therapeutics (LRMR) Ticks Higher to $2.02 as Shares Hold Above Key Support - Volume Profile
https://www.siam.in/ · 2026-10-16 -
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Yahoo · 2026-10-10 -
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Yahoo Finance · 2026-10-05 -
Larimar Therapeutics appoints John Harlow as COO
Seeking Alpha · 2026-09-29 -
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Yahoo Finance · 2026-09-29 -
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
Yahoo Finance · 2026-07-15 -
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
Yahoo Finance · 2026-07-08
No headlines in this category right now — try “All”.